1770
Moriah Woods Blvd.
Suite 18
Memphis, TN 38117-7126
USA
(901) 751-5966
fax - (901) 751-5966
e-mail - info@celltherapy.com
Under the direction of Dr. Peter Law, Cell Therapy, Inc. (CTI) has invested upwards of $30 million into research and development in an effort to bring Myoblast Transfer Therapy (MTT) to the market; and holds 150 issued or pending patents as depicted below (some cover several countries). CTI possesses the most comprehensive intellectual properties associated with cell therapy. The patents cover the production of myoblasts, application of myoblasts, production of medium for growth, transport, transplant and storage. CTI has also patented the automated method to produce myoblasts.
Following are the patents Peter K. Law has been issued over years. This represents the most valuable asset of Cell Therapy, Inc., as its cutting edge technology remains ahead of the competition.
| Patent Designation | Patent Number | Definition | Countries of Use |
| Compositions for and methods of treating muscle degeneration and weakness | U.S. 5,130,141 (issued) |
Broad pioneering patent in the field of myogenic cells and their use for repair of damaged muscle | United States |
| Cardiomyocytes for heart muscles damaged in heart attacks | U.S. Appl. No. 09/867,519 (pending) Singapore: Appl. No. 9801012-7 (pending) Aus.: (Appl. No. pending) |
Method for producing cardiomyocytes capable of proliferation, comprising providing cardiomyocyte cells; providing myoblast cells; and mixing the two types of cells under conditions that allow cell fusion of cardiomyocyte cells with myoblast cells to form heterokaryotic cardiomyocytes | United States Singapore |
| Myoblast therapy for mammalian diseases (1) | Aus.: 58311/99 (issued) China: Appl. No. 951925288 (PCT/US 95/16093)(issued) Aus.: Appl. No. 45976/96 (issued) Aus.: Appl. No. 2002300997 (pending) Can.: Appl. No. 2183167 (pending) Eur.: Appl. No. 95944088.4 (pending) |
Compositions and methods for repairing degenerating cells and replenishing lost cells in patients with hereditary degenerative diseases, in particular hereditary neuromuscular disorders | Australia, China, Canada, Europe (EPO) |
| Myoblast therapy for mammalian diseases (2) | U.S. Appl. No. 09/005,034 (issued) Singapore Appl. No. 9611231.3 (issued) PCT Appl. No. 9801012-7 (pending) 
|
Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal | United States Singapore (a PCT patent) |
| Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities | Eur.: EPO 0898967 (issued) France: (issued) Germany: (issued) UK: (issued) Italy: (issued) Switz. & Liechtenstein: (issued) Can.: Appl. No. 2,225,185 (pending) HK.: Appl. No. 99102199.7 (pending) Jap.: Appl. No. 10-227422 (pending) Mex.: Appl. No. 982560 (pending) U.S.: Appl. No. 09/132,321 (pending) U.S.: Appl. No. 09/986,344 (pending) |
A method of continuously supplying in vivo a peptide such as an opioid peptide, substance P receptor, or substance P analog | Europe (EPO), Canada, Hong Kong, Japan, Mexico, United States |
| Automated cell processor | U.S.: Patent No. 6,261,832 (issued) Singapore Patent No. 74036 (issued) |
An automated instrument for producing > a billion mammalian cells per run using stacked trays and tray tilting to move fluid into and out of the trays. | United States, Singapore (a PCT patent) |
| Myoblast therapy for cosmetic treatment | Singapore: Appl. No. 9801014-3 (issued) Australia: Appl. No. 748997 (issued) U.S.: Appl. No. 09/005,034 (issued) |
Myoblast cells can be grown up in huge quantities and added back, to fuse with other muscle cells and adipocytes (fat cells) to sculpt the body | Singapore, Australia, United States |
| Serum containing compositions and methods for cell culture and therapy | U.S. Provisional Patent Appl. No. 60/306,426 (pending) | Detailed methods and strategies for successful culture and manipulation of mammalian cells, and particularly myogenic cells in non-defined media. Growth media and procedures presented favor myogenic cell growth at the expense of fibroblast growth and are particularly useful for new therapies that combat heart disease and other muscle disorders | United States |
| Myogenic cell transfer catheter and method | W.O. 02/28470 A1 U.S. 60/231,880 (determined issuable) PCT/US01/28712 (pending) Singapore Appl. No. 200301162-4 (pending) Aus: Appl. No. 2002211230 (pending) Can: Appl. No. 79029-39 (pending) |
Cardiovascular catheters and methods of their use for automatically injecting large quantities of myogenic cells for repairing and augmenting muscle and other tissues. The catheters are "smart" devices with built in injection timing that allows easy and more accurate injection of cells from inside a beating heart for its repair | United States PCT |
| Heart regeneration | U.S. Provisional Patent Application. Foreign License Granted. |
Composition and methods for heart regeneration using angiomyogenesis | United States PCT |
| Biologic skin repair and enhancement | U.S. Provisional Patent Appl. No. 60/405,301 | Composition and methods for beautifying and strengthening skin | United States |
| Cellular Transplantation for heart regeneration | PCT/US03/95905 (pending) U.S. Provisional Patent Appl. No. 60/368,563 (pending) |
Angiomyogenesis of damaged hearts | PCT United States |
| Mechanisms of myoblast transfer in treating heart failure | PCT (Appl. No. pending) U.S. Provisional Patent Appl. No. 60/402,050 (pending) |
Transduced myoblasts to treat hear muscle degeneration, baldness and male sexual impotency | PCT United States |
| Myoblast treatment of diseased or weakened organs | U.S. (Appl. No. pending) PCT (Appl. No. pending) |
Cell therapy to treat and/or augment body structures | United States |
| Licensing Research Licenses
Commercial Licenses
|
|||